Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis

被引：0

作者：

Bewersdorf, Philipp ^{[1
,2
]}

Kewan, Tariq ^{[3
]}

Blaha, Ondrej ^{[4
,5
,6
]}

Stahl, Maximilian ^{[7
]}

Al Ali, Najla H. ^{[8
]}

DeZern, Amy E. ^{[9
]}

Sekeres, Mikkael A. ^{[10
]}

Uy, Geoffrey L. ^{[11
]}

Carraway, Hetty E. ^{[12
]}

Desai, Pinkal ^{[13
]}

Griffiths, Elizabeth A. ^{[14
]}

Stein, Eytan M. ^{[15
]}

Brunner, Andrew M. ^{[16
]}

McMahon, Christine M. ^{[17
]}

Zeidner, Joshua F. ^{[18
]}

Savona, Michael R. ^{[19
]}

Stempel, Jessica M. ^{[20
]}

Chandhok, Namrata Sonia ^{[21
]}

Ramaswamy, Rahul ^{[22
]}

Roboz, Gail J. ^{[23
]}

Rolles, Benjamin ^{[24
]}

Wang, Eunice S. ^{[14
]}

Harris, Amyah C. ^{[25
]}

Amaya, Maria L. ^{[26
]}

Hawkins, Hayley ^{[27
]}

Grenet, Justin ^{[28
]}

Gurnari, Carmelo ^{[29
]}

Shallis, Rory M. ^{[30
]}

Xie, Zhuoer ^{[31
]}

Maciejewski, Jaroslaw P. ^{[29
]}

Sallman, David A. ^{[31
]}

Della Porta, Matteo Giovanni ^{[32
]}

Komrokji, Rami S. ^{[8
]}

Zeidan, Amer M. ^{[33
,34
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Yale Univ, Sect Hematol, Dept Med, New Haven, CT USA

[3] Yale Univ, Sect Hematol, Dept Internal Med, New Haven, CT USA

[4] Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT USA

[5] Yale Univ, Sch Publ Hlth, Yale Ctr Analyt Sci, New Haven, CT USA

[6] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[7] Dana Farber Inst, Boston, MA USA

[8] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[9] Johns Hopkins Univ, Baltimore, MD USA

[10] Univ Miami, Sylvester Canc Ctr, Miami, FL USA

[11] Washington Univ, Div Oncol, Sch Med, St Louis, MO USA

[12] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Leukemia Program, Cleveland, OH USA

[13] Weill Cornell Med, New York, NY USA

[14] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[15] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY USA

[16] Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA USA

[17] Univ Colorado, Div Hematol, Sch Med, Aurora, CO USA

[18] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[19] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Med Ctr, Nashville, TN USA

[20] Yale Sch Med, Sect Hematol, Dept Internal Med, New Haven, CT USA

[21] Univ Miami, Div Hematol, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL USA

[22] Washington Univ, St Louis, MO USA

[23] New York Presbyterian Hosp, New York, NY USA

[24] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA

[25] Dana Farber Canc Inst, Boston, MA USA

[26] Univ Colorado, Div Hematol, Aurora, CO USA

[27] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[28] Weill Cornell, New York, NY USA

[29] Cleveland Clin, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH USA

[30] Yale Univ, Yale Sch Med, Sect Hematol, Dept Internal Med, New Haven, CT USA

[31] H Lee Moffitt Canc Inst, Tampa, FL USA

[32] IRCCS, Ctr Canc, Humanitas Res Hosp, Milan, Italy

[33] Yale Canc Ctr, Dept Internal Med, New Haven, CT USA

[34] Smilow Canc Hosp, New Haven, CT USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-178728

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：8

共 50 条

[21] Clinical Implications of TP53 Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate Database
Kewan, Tariq
Bewersdorf, Jan Philipp
Blaha, Ondrej
Stahl, Maximilian
Al Ali, Najla H.
DeZern, Amy E.
Sekeres, Mikkael A.
Carraway, Hetty E.
Desai, Pinkal
Griffiths, Elizabeth A.
Stein, Eytan M.
Brunner, Andrew M.
Amaya, Maria L.
Zeidner, Joshua F.
Savona, Michael R.
Stempel, Jessica M.
Chandhok, Namrata Sonia
Cochran, Hunter
Ramaswamy, Rahul
Singh, Abhay
Roboz, Gail J.
Rolles, Benjamin
Wang, Eunice S.
Harris, Amyah C.
Shallis, Rory M.
Xie, Zhuoer
Padron, Eric
Maciejewski, Jaroslaw P.
Della Porta, Matteo Giovanni
Komrokji, Rami S.
Sallman, David A.
Zeidan, Amer M.
BLOOD, 2023, 142
[22] Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program
Zeidan, Amer M.
Al-Kali, Aref
Borate, Uma
Cluzeau, Thomas
DeZern, Amy E.
Esteve, Jordi
Giagounidis, Aristoteles
Kobata, Krissy
Lyons, Roger
Platzbecker, Uwe
Sallman, David A.
Santini, Valeria
Sanz, Guillermo
Sekeres, Mikkael A.
Wei, Andrew H.
Xiao, Zhijian
Van Hoef, Marlies
Nourry-Boulot, Claire
Sadek, Islam
Bengoudifa, Bourras-Rezki
Sachs, Carolin
Sabo, John
Garcia-Manero, Guillermo
BLOOD, 2021, 138
[23] ECONOMIC IMPACT AND HEALTHCARE UTILIZATION IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) - A CLAIMS DATABASE STUDY
Bell, J.
Galaznik, A.
Farrelly, E.
Blazer, M.
Shih, H. -C.
Raju, A.
Ogbonnaya, A.
Eaddy, M.
Fram, R.
Faller, D.
HAEMATOLOGICA, 2017, 102 : 486 - 486
[24] TREATMENT PATTERNS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) - A CLAIMS DATABASE STUDY
Bell, J.
Galaznik, A.
Farrelly, E.
Blazer, M.
Shih, H-C.
Raju, A.
Ogbonnaya, A.
Eaddy, M.
Fram, R.
Faller, D.
HAEMATOLOGICA, 2017, 102 : 491 - 492
[25] Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)
Garcia-Manero, Guillermo
Jonasova, Anna
Luger, Selina M.
Al-Kali, Aref
Valcarcel, David
Warlick, Erica D.
Jedrzejczak, Wieslaw W.
Diez-Campelo, Maria
Zbyszewski, Patrick S.
Cavanaugh, Christopher
Woodman, Richard C.
Fruchtman, Steven M.
Takahashi, Koichi
BLOOD, 2019, 134
[26] SYSTEMATIC REVIEW OF THERAPY USED IN HIGHER-RISK (HR) MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
Bell, J.
Galaznik, A.
Huelin, R.
Stokes, M.
Seal, B.
Fram, R.
Faller, D. V.
LEUKEMIA RESEARCH, 2017, 55 : S80 - S81
[27] NOVEL PREDICTIVE INDICATORS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC NEOPLASMS (HR-MDS) TREATED WITH 5-AZACYTIDINE: CUMULATIVE DATA FROM THE HELLENIC MDS STUDY GROUP
Kotsianidis, I.
Hatzimichael, E.
Pappa, V.
Galanopoulos, A.
Kourakli, A.
Diamantopoulos, P.
Papageorgiou, S.
Liapis, K.
Papadopoulos, V.
Papoutselis, M.
Bouchla, A.
Georgoulis, V.
Vassilakopoulos, T.
Solomou, E.
Dimou, M.
Vassilopoulos, G.
Vardi, A.
Papaioannou, M.
Pontikoglou, C.
Anagnostopoulos, A.
Panayiotidis, P.
Kontopidou, F.
Harchalakis, N.
Adamopoulos, N.
Ximeri, M.
Zikos, P.
Megalakaki, A.
Repousis, P.
Kotsopoulou, M.
Dryllis, G.
Tsoukanas, D.
Kyrtsonis, M. -C.
Poulakidas, E.
Bouronikou, E.
Delimpasis, S.
Mparmparousi, D.
Papadaki, H.
Vyniou, N. A.
Symeonidis, A.
LEUKEMIA RESEARCH, 2023, 128
[28] Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS)
Chen, James
Johnson, Lisa
McKenna, Kelly
Choi, Timothy
Duan, Jiaqi
Feng, Dongdong
Tsai, Jonathan
Garcia-Martin, Natalia
Sompalli, Kavitha
Maute, Roy
Vyas, Paresh
Majeti, Ravindra
Takimoto, Chris
Liu, Jie
Ramsingh, Giridharan
Chao, Mark
Volkmer, Jens-Peter
Weissman, Irving
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S317 - S318
[29] Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Hypomethylating Agents (HMA)
Jabbour, Elias
Kantarjian, Hagop M.
Qiao, Wei
Strati, Paolo
Khan, Navira F.
Cortes, Jorge E.
Hoehn, Daniela
Hu, Jianhua
Obrien, Susan
Bryan, Jeffrey
Prescott, Hillary
DiNardo, Courtney D.
Daver, Naval
Kadia, Tapan M.
Garcia-Manero, Guillermo
BLOOD, 2013, 122 (21)
[30] PATIENT-CENTRIC CARE (PCC) IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS): A GLOBAL SYSTEMATIC LITERATURE REVIEW (SLR) AND GAP ANALYSIS
Armstrong, E. P.
Franic, D.
Malone, D. C.
Pham, S., V
Hogea, C.
VALUE IN HEALTH, 2023, 26 (06) : S334 - S334

← 1 2 3 4 5 →